Metastatic Colorectal Cancer

The pension plan known as a cash balance plan may help physicians reduce their practices’ and their own taxable income. A review of how this plan works and its potential benefits was the top story in hematology/oncology last week.

The FDA granted fast track designation to arfolitixorin for treatment of patients with metastatic colorectal cancer.

A phase 3 trial designed to assess trifluridine and tipiracil plus bevacizumab as first-line treatment for certain patients with advanced colorectal cancer missed its primary endpoint.

The FDA cleared an investigational new drug application for GCC19CART, a chimeric antigen receptor T-cell therapy designed to treat patients with relapsed or refractory metastatic colorectal cancer.

Maintenance therapy with 5-fluoruracil/leucovorin plus panitumumab better maintained wildtype metastatic colorectal cancer than 5-fluoruracil/leucovorin alone, according to data from a study presented at ASCO21.

Overall survival of patients with metastatic colorectal cancer who completed 16 weeks of first-line chemotherapy treatment was unaffected by oral maintenance of capecitabine compared with no treatment, according to data from phase 3 trial presented at ASCO21.

Liquid biopsy-driven rechallenge with panitumumab led to objective responses in about one-third of patients with metastatic colorectal cancer, according to results of the phase 2 CHRONOS study presented at the virtual ASCO Annual Meeting.

Although colorectal cancer mortality has declined steadily since the 1940s, the long-term prognosis for patients with late-stage metastatic disease has remained relatively poor.

An allogeneic chimeric antigen T-cell therapy showed evidence of clinical activity among patients with metastatic colorectal cancer, according to results of a dose-escalation study presented at Gastrointestinal Cancers Symposium.

Pembrolizumab monotherapy demonstrated superior PFS and PFS2 compared with standard-of-care chemotherapy among patients with microsatellite-instability high/mismatch repair-deficient metastatic colorectal cancer.